production and evaluation of specific single-chain antibodies against ctla-4 for cancer-targeted therapy
Authors
abstract
background: cytotoxic t lymphocyte–associated antigen 4 (ctla-4) molecules are expressed on t-cells and inhibit their function by inhibiting activation of subsequent t-cell molecular pathways. blocking of ctla-4 inhibits the growth of malignant tumor cells. anti-ctla-4 monoclonal antibodies activate the immune system against cancer. due to several advantages of single-chain antibodies (scfvs) compared to monoclonal antibodies in cancer immunotherapy, specific anti-ctla-4 scfvs (single-chain variable fragment) were selected in this study. methods: a phage antibody display library of scfvs was analyzed and a panning process was performed against an immunodominant epitope of ctla-4. pcr and dna fingerprinting were used to differentiate the specific clones. the specificity of the selected clones was investigated by phage elisa (enzyme-linked immunosorbent assay). results: two specific clones with frequencies of 35 and 20% were identified. the clones reacted with the corresponding epitope on elisa, while no reactivity was observed with an unrelated peptide, m13ko7 helper phage, unrelated scfvs, or no peptide as negative controls. conclusions: targeted therapy against cancer markers is an ideal treatment strategy. specific human anti-ctla-4scfvs were selected in this study. these scfvs bound the related epitope. these antibodies have the potential to be used for targeted therapy, where the blocking of ctla4 receptor is needed. the study suggests further evaluation of the selected scfvs to reveal the effects of the selected antibodies.
similar resources
Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy
Background: Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) molecules are expressed on T-cells and inhibit their function by inhibiting activation of subsequent T-cell molecular pathways. Blocking of CTLA-4 inhibits the growth of malignant tumor cells. Anti-CTLA-4 monoclonal antibodies activate the immune system against cancer. Due to several advantages of single-chain antibodi...
full textSelection and Evaluation of Specific Single Chain Antibodies against CD90, a Marker for Mesenchymal and Cancer Stem Cells
Background: CD90, a membrane-associated glycoprotein is a marker used to identify mesenchymal stem cells (MSCs). Recent studies have introduced CD90, which induces tumorigenic activity, as a cancer stem cell (CSC) marker in various malignancies. Blocking CD90 activity with anti-CD90 monoclonal antibodies enhanced anti-tumor effects. To date, highly specific antibody single-chain variable fragme...
full textCTLA-4 Antibodies in Cancer Immunotherapy
Activating human immune system to battle cancer has been a focus of cancer immunotherapy research from quite some time. After decades of disappointment, the tide has finally changed with some recent successes in clinical trials. The first such approach with clinical success is cytotoxic T lymphocyte antigen-4 (CTLA4) antibody therapy which aims to relieve the immune suppressive effects of CTLA-...
full textDesign, Synthesis and Biological Evaluation of Ketoprofen Conjugated To RGD/NGR for Targeted Cancer Therapy
It is well known that Arginine-Glycine-Aspartic acid (RGD) and Asparagine-Glycine-Arginine (NGR) peptides preferentially bind to integrin receptors and aminopeptidase Nrespectively and these two receptors play important roles in angiogenesis. Therefore ketoprofenas a non-selective cox Inhibitor was conjugated with linear RGD and NGR to take advantageof targeting capability of these two motifs a...
full textDesign, Synthesis and Biological Evaluation of Ketoprofen Conjugated To RGD/NGR for Targeted Cancer Therapy
It is well known that Arginine-Glycine-Aspartic acid (RGD) and Asparagine-Glycine-Arginine (NGR) peptides preferentially bind to integrin receptors and aminopeptidase Nrespectively and these two receptors play important roles in angiogenesis. Therefore ketoprofenas a non-selective cox Inhibitor was conjugated with linear RGD and NGR to take advantageof targeting capability of these two motifs a...
full textProduction of Erythropoietin-specific polyclonal Antibodies
Background: Erythropoietin, as a principal hormone promotes red blood cell production in bone marrow. Varieties of erythropoietin biosimilar are being produced by recombinant DNA technology in cell cultures. The detection or quantification of these molecules are being performed by diff erent methods which some of theme such as Western blot and enzymelinked immunosorbent assay (ELISA) require sp...
full textMy Resources
Save resource for easier access later
Journal title:
reports of biochemistry and molecular biologyجلد ۶، شماره ۱، صفحات ۸-۱۴
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023